The FDA has expanded the Emergency Use Authorizations (EUAs) for the mRNA-based COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) to include administration of a third dose in persons ≥12 years old (Pfizer/BioNTech) or ≥18 years old (Moderna) who have undergone solid organ transplantation or have a condition that compromises the immune system to a similar extent (see Table 1).1

Immunocompromised persons are more likely than healthy individuals to have an inadequate antibody response to COVID-19 vaccination, breakthrough SARS-CoV-2 infection, and severe COVID-19 requiring hospitalization....  Continue reading

More from Issue 1633
Previous Issue: 1632      September 6, 2021
Coming Soon
Treatment of Onychomycosis
A New Indication for Empagliflozin (Jardiance)
Bamlanivimab and Etesevimab for Post-Exposure Prophylaxis of COVID-19
Trilaciclib (Cosela) to Prevent Myelosuppression in Small Cell Lung Cancer
Follow us   Twitter LinkedIn YouTube Blog RSS   Email Alerts
Advance Release

Annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication.1 Available influenza vaccines for the 2021-2022 season are listed in Table 2.

Vaccination of all eligible persons can reduce the prevalence of influenza illness and symptoms that might be confused with ... Continue reading